Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today

After reporting that the Food and Drug Administration has accepted the application for approval of bempedoic acid, its new cholesterol-lowering treatment, Esperion Therapeutics (NASDAQ: ESPR) saw its shares trade 11.5% higher at 1:30 p.m. EDT on Monday.